Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Trading Down 5.3 %

Shares of Lipocine stock opened at $4.30 on Friday. The company has a market cap of $23.01 million, a PE ratio of -5.66 and a beta of 1.18. The company has a 50 day moving average of $5.07 and a 200-day moving average of $5.61. Lipocine has a 1-year low of $2.40 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Research analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.